ライフサイエンスコーパス: ventilator

1 splant-free survival and longer times on the ventilator.

2 ventilation in conjunction with a mechanical ventilator.

3 ssment and management of the patient and the ventilator.

4 ention to access the international supply of ventilators.

5 sted ventilation, and a bench study with six ventilators.

6 ncluding 338 to 1608 ICU beds and 118 to 599 ventilators.

7 uire medical attention, hospitalization, and ventilators.

8 rty patients (56.6%) were liberated from the ventilator, 16 (30.2%) have been discharged alive, 7 (13

9 ge, 53.7% of patients were detached from the ventilator and 1-year survival was 66.9%.

10 outcomes and may hasten liberation from the ventilator and from ICU.

11 %) required ICU admission, 1 (3%) required a ventilator, and none died during their hospital admissio

12 Primary end point was ventilator- and vasopressor-free days within 30 days (de

13 ficant differences in the primary end point (ventilator- and vasopressor-free days: 15.0 vs 14.5 in t

14 pital beds, intensive care units (ICUs), and ventilators are vital for the treatment of patients with

15 eurologic assessment at admission, confirmed ventilator-assisted pneumonia, median ICU stay, median h

16 nical trials (RCTs) in hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP

17 tin/relebactam in treating hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP).

18 ital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

19 ntilator-associated event, infection-related ventilator-associated complication, and probable ventila

20 Sixteen (12%) and 10 (8%) had ventilator-associated condition by 2013 Adult and Draft

21 pneumonia criteria applied in real time and ventilator-associated condition criteria applied retrosp

22 Condition criteria, the new Draft Pediatric Ventilator-Associated Condition criteria, and physician-

23 tilator-associated pneumonia, the 2013 Adult Ventilator-Associated Condition criteria, the new Draft

24 The quarterly mean ventilator-associated event rate significantly decreased

25 vidence-based interventions and decreases in ventilator-associated event, infection-related ventilato

26 te affirming that best practices can prevent ventilator-associated events.

27 y funded a two-state collaborative to reduce ventilator-associated events.

28 ile (4.5% vs 1.7%), and incidence density of ventilator-associated pneumonia (2.4/1,000 patient-days

29 served with respect to the incidence of late ventilator-associated pneumonia (4% and 5%, respectively

30 The most common infection type was ventilator-associated pneumonia (52%); 7% of patients we

31 The primary outcome was early ventilator-associated pneumonia (during the first 7 days

32 When adjusted on prognostic variables, ventilator-associated pneumonia (hazard ratio, 1.38 (1.2

33 sing nutritional support was associated with ventilator-associated pneumonia (relative risk, 1.19; 95

34 cheostomy presented less risk difference for ventilator-associated pneumonia (risk difference, 0.78;

35 patients started on antibiotics for possible ventilator-associated pneumonia (VAP) do not have pneumo

36 Ventilator-associated pneumonia (VAP) is the commonest h

37 acteria are considered the primary causes of ventilator-associated pneumonia (VAP), a severe hospital

38 occus aureus (MRSA) is an important cause of ventilator-associated pneumonia (VAP).

39 or more than 48 hours, 7,735 were at risk of ventilator-associated pneumonia and 9,747 were at risk o

40 ing; the effect of proton pump inhibitors on ventilator-associated pneumonia and C. difficile remain

41 The impact was similar for ventilator-associated pneumonia and ICU-hospital-acquire

42 Ventilator-associated pneumonia and ICU-hospital-acquire

43 on cause of infection in cystic fibrosis and ventilator-associated pneumonia and in burn and wound pa

44 the 133 eligible participants, 24 (18%) had ventilator-associated pneumonia by 2008 Pediatric criter

45 Although 20 participants were diagnosed with ventilator-associated pneumonia by 2008 Pediatric criter

46 f a COVID-19 patient who developed recurring ventilator-associated pneumonia caused by Pseudomonas ae

47 s Centers for Disease Control and Prevention ventilator-associated pneumonia criteria and physician d

48 Ventilator-associated pneumonia criteria applied in real

49 y fewer and different patients than previous ventilator-associated pneumonia criteria or physician di

50 Ventilator-associated pneumonia developed in 20.4% of pa

51 e prophylaxis in the context of experimental ventilator-associated pneumonia due to methicillin-resis

52 travenous phage therapy for the treatment of ventilator-associated pneumonia due to methicillin-resis

53 Condition criteria, and physician-diagnosed ventilator-associated pneumonia in a cohort of PICU pati

54 Ventilator-associated pneumonia is the most common inten

55 Ventilator-associated pneumonia is the most important in

56 -proven aspiration pneumonia and early-onset ventilator-associated pneumonia occurred in 54 patients

57 ation in the 2 days before the occurrence of ventilator-associated pneumonia or ICU-hospital-acquired

58 The first three episodes of ventilator-associated pneumonia or ICU-hospital-acquired

59 lation, and had nosocomial pneumonia (either ventilator-associated pneumonia or ventilated hospital-a

60 ults showed that early mobilization improved ventilator-associated pneumonia patients' Medical Resear

61 rgillus infection in patients with suspected ventilator-associated pneumonia remains uncharacterized

62 xhaled gas were compared and correlated with ventilator-associated pneumonia severity.

63 n mobility spectrometry is able to detect 1) ventilator-associated pneumonia specific changes and 2)

64 mobility spectrometry for early detection of ventilator-associated pneumonia specific volatile organi

65 hythm resulted in a lower incidence of early ventilator-associated pneumonia than placebo.

66 in the composition of exhaled gas we induced ventilator-associated pneumonia via endobronchial instil

67 oalveolar lavage fluid from all patients and ventilator-associated pneumonia was confirmed by at leas

68 The incidence of early ventilator-associated pneumonia was lower with antibioti

69 lidated cutoff, clinicians were advised that ventilator-associated pneumonia was unlikely and to cons

70 Using a rabbit model of ventilator-associated pneumonia we determined if gas chr

71 hat both ICU-hospital-acquired pneumonia and ventilator-associated pneumonia were associated with an

72 After adjudication, 60 cases of ventilator-associated pneumonia were confirmed, includin

73 atients with nosocomial pneumonia (including ventilator-associated pneumonia) caused by Gram-negative

74 Adults with nosocomial pneumonia (including ventilator-associated pneumonia), enrolled at 136 centre

75 Overall, 519 (71%) patients had ventilator-associated pneumonia, 239 (33%) had Acute Phy

76 fied acute physiology score II, diagnosis of ventilator-associated pneumonia, and infection by multid

77 nit (ICU) most commonly manifests as sepsis, ventilator-associated pneumonia, and infection of surgic

78 infections, including hospital-acquired and ventilator-associated pneumonia, are common in hospitali

79 echanical ventilation, such as pneumothorax, ventilator-associated pneumonia, atelectasis, and pleura

80 atients with nosocomial pneumonia, including ventilator-associated pneumonia, compared with meropenem

81 Hospitalized patients with hospital-acquired/ventilator-associated pneumonia, complicated intraabdomi

82 sive care unit-related complications such as ventilator-associated pneumonia, deep vein thrombosis, a

83 We identified 32 ventilator-associated pneumonia, eight urinary tract inf

84 d when investigating patients with suspected ventilator-associated pneumonia, including patient group

85 ontrol and Prevention Pediatric criteria for ventilator-associated pneumonia, the 2013 Adult Ventilat

86 ematological parameters supporting suspected ventilator-associated pneumonia.

87 idated as effective markers for exclusion of ventilator-associated pneumonia.

88 rdship in patients with clinically suspected ventilator-associated pneumonia.

89 hat is associated with hospital-acquired and ventilator-associated pneumonia.

90 nt in vivo fitness cost in a murine model of ventilator-associated pneumonia.

91 use remains high in patients with suspected ventilator-associated pneumonia.

92 tilated for at least 48 h, and had suspected ventilator-associated pneumonia.

93 haled gas could give an earlier diagnosis of ventilator-associated pneumonia.

94 h shockable rhythm are at increased risk for ventilator-associated pneumonia.

95 umonia were confirmed, including 51 of early ventilator-associated pneumonia.

96 judication committee determined diagnoses of ventilator-associated pneumonia.

97 ilator-associated complication, and probable ventilator-associated pneumonia.

98 ubglottic secretions plays a pivotal role in ventilator-associated pneumonia.

99 underscoring its potential in the context of ventilator-associated pneumonia.

100 pergillus infection in adults with suspected ventilator-associated pneumonia.Methods: Two prospective

101 Patient-ventilator asynchrony is common among critically ill pat

102 ve tidal volumes and common forms of patient-ventilator asynchrony, and that artifact correction sign

103 rally adjusted ventilatory assist on patient-ventilator asynchrony, other physiologic variables, and

104 on at an LTACH, 53.7% were detached from the ventilator at discharge and 1-year survival was 66.9%.

105 , with 4.8% of patients (8/165) still on the ventilator at the time of this report.

106 ear of transplant were patient on mechanical ventilator before transplantation, prior liver transplan

107 maximal EtCO(2) recorded between consecutive ventilator breaths best reflects alveolar CO(2).

108 Maximal EtCO(2) recorded between ventilator breaths reflected alveolar CO(2) (bench).

109 for P0.1vent compared with P0.1ref for most ventilators but precision varied; in patients, precision

110 tals, 351 skilled nursing facilities, and 12 ventilator-capable skilled nursing facilities) in the Ch

111 bapenemase-producing organisms (CPOs) at one ventilator-capable skilled nursing facility (vSNF-A).

112 We analyzed the ventilator characteristics of a large cohort of fibrotic

113 , and 3) how P0.1vent displayed by different ventilators compares to a "reference" P0.1 (P0.1ref) mea

114 ce care (18.6% vs 4.9%; p < 0.01) with fewer ventilator days (median 4 vs 6 d; p < 0.05), tracheostom

115 ity rates, intensive care unit bed days, and ventilator days from individual review of electronic med

116 Median postoperative ventilator days were 0 (0-1), intensive care 2 (1-3), an

117 tay, intensive care unit length of stay, and ventilator days) did not differ between groups.

118 mechanically ventilated patients with 75,621 ventilator days.

119 decreased from 7.34 to 4.58 cases per 1,000 ventilator-days after 24 months of implementation (p = 0

120 come countries (18.5, 15.2, and 9.0 per 1000 ventilator-days, respectively).

121 nt; 95% confidence interval [CI], .98-1.36), ventilator death (HR, 0.82 [95% CI, .55-1.22]), time to

122 Pre-operative ventilator dependence and airway secretion accumulation

123 Prevalences of comorbidities, ventilator dependence, and severity of acute illness wer

124 structive pulmonary disease, cancer, sepsis, ventilator dependence, functional status), and age.

125 atory muscle, the diaphragm, contributing to ventilator dependence.

126 routine NIV users, taking into consideration ventilator dependence.

127 Prevalence of comorbidities, ventilator-dependence, and severity of acute illness wer

128 erative respiratory failure (RF), defined as ventilator dependency for more than 48 hours or unplanne

129 or birth weight of less than 1250 g who were ventilator dependent between 7 and 14 days of life, with

130 in physiology are not usually considered in ventilator design and testing.

131 matched pairs analysis revealed that time on ventilator (difference of median, 98.5 hr; p = 0.003) an

132 the relative contributions of mortality and ventilator duration on the composite effect size.

133 Ventilators estimating P0.1vent without occlusions could

134 CU stay greater than 24 hours, who were on a ventilator for more than 24 hours and less than 14 days.

135 four trials (n = 2,410 patients), Alive and Ventilator Free and ventilator-free days score had simil

136 o interpretation of differences in Alive and Ventilator Free are also presented.

137 Alive and Ventilator Free compares each patient with every other p

138 Alive and Ventilator Free is less prone to favor a treatment with

139 Alive and Ventilator Free less often found in favor of treatments

140 erarchical composite endpoint, the Alive and Ventilator Free score.

141 days score had similar power, with Alive and Ventilator Free slightly more powerful when a mortality

142 We evaluated power of Alive and Ventilator Free versus ventilator-free days score under

143 A hierarchical composite endpoint, Alive and Ventilator Free, preserves statistical power while impro

144 oups had poorer clinical outcomes with fewer ventilator-free days (-2.18, p = 0.008) and (-3.49, p <

145 oup, compared with placebo, had fewer median ventilator-free days (1 day [IQR 0 to 17] in the KGF gro

146 eous breathing was associated with increased ventilator-free days (13 [0-22] vs 8 [0-20]; p = 0.014)

147 nia (4% and 5%, respectively), the number of ventilator-free days (21 days and 19 days), ICU length o

148 tal mortality (75% vs 53.4%; p = 0.26), more ventilator-free days (9 [0-21.5] vs 0 [0-12]; p = 0.16),

149 CI, 5.0-8.2) during the first 28 days vs 4.0 ventilator-free days (95% CI, 2.9-5.4) in the standard c

150 ed to the dexamethasone group had a mean 6.6 ventilator-free days (95% CI, 5.0-8.2) during the first

151 e injury, and thereby increase the number of ventilator-free days (days alive and free from mechanica

152 ically significant increase in the number of ventilator-free days (days alive and free of mechanical

153 th increased lung bacterial burden had fewer ventilator-free days (hazard ratio, 0.43; 95% confidence

154 in the higher PEEP group had a median of 17 ventilator-free days (IQR, 0-27 days) (mean ratio, 1.04;

155 s in the lower PEEP group had a median of 18 ventilator-free days (IQR, 0-27 days) and 493 patients i

156 itment and control ventilation strategies in ventilator-free days (median, 16 d [interquartile range

157 tio, 0.90; 95% CI, 0.63-1.30; p = 0.585), or ventilator-free days (odds ratio, 1.06; 95% CI, 0.71-1.5

158 unity composition of lung bacteria predicted ventilator-free days (P = 0.003), driven by the presence

159 hospital mortality (p = 0.004) and 2.5 fewer ventilator-free days (p = 0.044), compared with fluid ov

160 Ventilator-free days (VFDs) are a commonly reported comp

161 fungemia, ICU length of stay, mortality, and ventilator-free days (VFDs) at 28 days.

162 tality (primary outcome), ICU mortality, and ventilator-free days and alive at day 28 were retrospect

163 ed for other key clinical variables, such as ventilator-free days and mortality at day 28.

164 ospital mortality as the primary outcome and ventilator-free days as the secondary outcome, we tested

165 Mortality models also stratified ventilator-free days at 28 days in both derivation and v

166 me was a score combining death and number of ventilator-free days at day 28 (score ranged from -1 for

167 (95% CI, 1.3-3.0), as well as an increase in ventilator-free days at day 28 by 3.7 days (95% CI, 3.1-

168 noninferiority margin for the difference in ventilator-free days at day 28 of -10%.

169 edian composite score of death and number of ventilator-free days at day 28 was 10 days (interquartil

170 The primary outcome was the number of ventilator-free days at day 28, with a noninferiority ma

171 r PEEP strategy with regard to the number of ventilator-free days at day 28.

172 ts and Main Results: The primary outcome was ventilator-free days at Day 28.

173 The number of ventilator-free days did not differ significantly betwee

174 The number of ICU-free days and of ventilator-free days did not differ significantly betwee

175 The primary outcome was ventilator-free days during the first 28 days, defined a

176 The primary outcome was the number of ventilator-free days from randomization until day 28.

177 ciated with higher mortality rates and fewer ventilator-free days in comparison to both mild hyperoxi

178 luid-conservative therapy has also increased ventilator-free days in patients with ARDS.

179 a maximal lung recruitment strategy reduces ventilator-free days in patients with ARDS.Methods: A ph

180 ere detected in the airways of children with ventilator-free days less than 20 days.

181 site score that included death and number of ventilator-free days over 28 days.

182 410 patients), Alive and Ventilator Free and ventilator-free days score had similar power, with Alive

183 when a mortality difference was present, and ventilator-free days score slightly more powerful with a

184 ed power of Alive and Ventilator Free versus ventilator-free days score under various circumstances.

185 Ventilator-free days through day 28 and mortality at 28

186 Ventilator-free days was used as primary outcome measure

187 Mean (SD) ventilator-free days were 18.1 (10.8) in the emergency d

188 ot result in improvement in vasopressor- and ventilator-free days within 30 days.

189 The "ventilator-free days" score, is an established composite

190 The primary outcome was ventilator-free days, determined at 28 days after admiss

191 We compared 90-day mortality, ventilator-free days, ICU-free days, and hospital-free d

192 17-0.83; p = 0.02) and a 3.9 day increase in ventilator-free days, p value equals to 0.01.

193 els of airway NETs are associated with fewer ventilator-free days.

194 trate utility for composite outcomes such as ventilator-free days.

195 ital length of stay, ICU length of stay, and ventilator-free days.

196 erity of organ dysfunction, or the number of ventilator-free days.

197 e number of ICU-free days, and the number of ventilator-free days.

198 , did not significantly affect the number of ventilator-free days.

199 hics, preextracorporeal membrane oxygenation ventilator, hemodynamic and biochemical parameters, extr

200 cate intensive care unit beds and mechanical ventilators if the supply of these resources is insuffic

201 rates are associated with longer time on the ventilator independent of oxygenation defect severity.

202 Mechanical ventilation can cause ventilator-induced brain injury via afferent vagal signa

203 present a novel strategy to prevent or treat ventilator-induced brain injury.

204 urinergic receptors (P2X) act as triggers of ventilator-induced brain injury.

205 receptors are involved in the mechanisms of ventilator-induced brain injury.

206 RATIONALE: Ventilator-induced diaphragm dysfunction is a significan

207 ransvenous phrenic nerve pacing may mitigate ventilator-induced diaphragm dysfunction.

208 l ventilation has been proposed to attenuate ventilator-induced diaphragm dysfunction.

209 tive stress are among the major effectors of ventilator-induced diaphragm muscle dysfunction (VIDD),

210 We evaluated early and late recoveries from ventilator-induced diaphragmatic dysfunction in a mouse

211 imary diaphragmatic dysfunction, also termed ventilator-induced diaphragmatic dysfunction.

212 Furthermore, how to minimize ventilator-induced lung injury (VILI) for any given lung

213 ey factors shown experimentally to influence ventilator-induced lung injury (VILI).

214 However, MV can also cause ventilator-induced lung injury (VILI).

215 rotective strategy, which aims at minimizing ventilator-induced lung injury (with low Vt/high positiv

216 ventilation heterogeneity may contribute to ventilator-induced lung injury during high-frequency osc

217 The potential for ventilator-induced lung injury during high-frequency osc

218 mption of a high-fat diet protects mice from ventilator-induced lung injury in a manner independent o

219 Hydrogen sulfide reduces ventilator-induced lung injury in mice.

220 rway pressure ventilation strategy mitigates ventilator-induced lung injury in patients with severe a

221 Fat-fed mice showed clear attenuation of ventilator-induced lung injury in terms of respiratory m

222 Ventilator-induced lung injury may occur in acute respir

223 y develop lung injury that is similar to the ventilator-induced lung injury observed in mechanically

224 limit or reverse a potentially accelerating ventilator-induced lung injury process.

225 Ventilator-induced lung injury remains a key contributor

226 use circulatory depression and contribute to ventilator-induced lung injury through alveolar overdist

227 This "ventilator-induced lung injury vortex" of the shrinking

228 risk for respiratory distress, asynchronies, ventilator-induced lung injury, diaphragmatic injury, an

229 ion, the respiratory rate per se may promote ventilator-induced lung injury, dynamic hyperinflation,

230 In a classic model of ventilator-induced lung injury, high peak pressure (and

231 ad assessed interventions likely to decrease ventilator-induced lung injury, including low tidal volu

232 ONALE: In the original 1974 in vivo study of ventilator-induced lung injury, Webb and Tierney reporte

233 ary biotrauma, which couldtherefore decrease ventilator-induced lung injury.

234 he physiologic prerequisites for controlling ventilator-induced lung injury.

235 osed as indicators, and possibly drivers, of ventilator-induced lung injury.

236 and minimize/abolish the harmful effects of ventilator-induced lung injury.

237 me and driving pressure, key determinants of ventilator-induced lung injury.

238 ation strategies aimed at further minimizing ventilator-induced lung injury.

239 y observed in patients with ARDS by creating ventilator-induced lung injury.

240 plasma biomarkers as a surrogate outcome for ventilator-induced lung injury.

241 The average time from tracheostomy to ventilator liberation was 11.8 days +/- 6.9 days (range

242 ytopenia, preexisting kidney disease, failed ventilator liberation, and acute kidney injury +/- hemod

243 except preexisting kidney disease and failed ventilator liberation, were measured at the time the pat

244 ercapnic acidosis refractory to conventional ventilator management strategies.

245 stays in the intensive care unit, prolonged ventilator management, and possible dialysis and tracheo

246 d gas (ABG) results, ventilator settings and ventilator measurements are discussed and addressed.

247 ow cytometry, and the flexiVent small-animal ventilator.Measurements and Main Results: The nanopartic

248 all mechanically ventilated patients and all ventilator modes, it is a potentially more useful predic

249 om -1 for death to 27 if the patient was off ventilator on the first day).

250 Objectives: To determine 1) the validity of "ventilator" P0.1 (P0.1vent) displayed on the screen as a

251 breathing reduced via a proportional assist ventilator (PAV).

252 Ventilator pressure increases noncystic lung Vt, but ins

253 Significant reductions in ventilator pressure-time-product were achieved during st

254 An emergency department ventilator protocol which targeted variables in need of

255 Detailed ventilator records in the electronic health record provi

256 evaluated more than 26.7 million changes to ventilator settings (approximately 150,000 per patient)

257 ective ventilation evaluated on standardized ventilator settings 24 hours after acute respiratory dis

258 t a quantifiable Vt that will correlate with ventilator settings and clinical outcomes.Methods: Magne

259 ounds, all arterial blood gas (ABG) results, ventilator settings and ventilator measurements are disc

260 Ventilator settings for patients with severe acute respi

261 rove our understanding of optimal mechanical ventilator settings in acute lung injury.

262 Patients with minimal and stable ventilator settings may be suitable candidates for early

263 Assessing serial ventilator settings may help clinicians identify candida

264 he degree of hypoxemia and/or the effects of ventilator settings on gas exchange.

265 nical recordings were obtained and different ventilator settings tested.

266 riving pressure for minimization resulted in ventilator settings that also reduced mechanical power a

267 ts with suspected VAP but minimal and stable ventilator settings treated with 1-3 days vs >3 days of

268 The median home ventilator settings were an inspiratory positive airway

269 Mechanical ventilator settings, arterial blood gases, vital signs,

270 ventilatory manoeuvres, including changes in ventilator settings, suctioning, chest drains, positioni

271 es as targets to derive maximally protective ventilator settings.

272 e is known about baseline characteristics or ventilator strategies that might improve outcomes.

273 assist device use (16% versus 30%; P=0.017), ventilator support (0% versus 6%; P=0.031), and donor ra

274 eaths/minute) was common (56%); 21% required ventilator support and 18% were admitted to intensive ca

275 ssociated with a greater need for mechanical ventilator support and higher hospital mortality.

276 Gestational diabetes and both mechanical ventilator support and PVD at 7 days were associated wit

277 th coronavirus disease 2019 who will require ventilator support as well as those associated with 30-d

278 The combination of PVD and mechanical ventilator support at 7 days was among the strongest pro

279 tum women found that more than half required ventilator support, 2 women died, and 6 infants were bor

280 40%) spent time in the ICU, 7 (18%) required ventilator support, and 2 (5%) died during their hospita

281 utcomes including ICU admittance, mechanical ventilator support, and a high rate of mortality.

282 spiratory distress syndrome (ARDS) requiring ventilator support.

283 espiratory symptoms, and no patient required ventilator support.

284 1% in intensive care units, and 17.6% needed ventilator support.

285 atory mode that may lead to improved patient-ventilator synchrony.

286 adjusted ventilatory assist improves patient-ventilator synchrony; however, its effects on clinical o

287 HCR reduces bleeding, ventilator time, and length of stay compared with tradit

288 Over one half of respondents did not have ventilator triage policies.

289 Many institutions are developing ventilator triage policies.

290 Longer duration of ventilator usage and hospitalization was associated with

291 disease, intensive care unit admission, and ventilator use) were associated with euro 4160 (95% CI,

292 ltivariable analysis, older age, dialysis or ventilator use, and lower albumin were associated with h

293 irth, need for supplemental oxygen, neonatal ventilator use, and neonatal resection (p < 0.001).

294 bles, including age at HT, diagnosis, pre-HT ventilator use, extracorporeal membrane oxygenation, inh

295 When controlling for ventilator use, sex, and comorbid conditions, FIB-4 >=2.

296 g disease characteristics, demographics, and ventilator variables were analyzed for univariable and m

297 Standard physical therapy delivered in a ventilator weaning facility failed to improve quadriceps

298 conventional physical therapy provided at a ventilator weaning facility would increase quadriceps st

299 e than or equal to 14 days, 2) admitted to a ventilator weaning unit, or 3) received a tracheostomy f

300 y predicted that 8 intensive-care beds and 7 ventilators would be sufficient to treat GBS cases.